Figure S3. BCL2 and BCL-xL levels in HL60 and KG1a following Vehicle (Cont), 1.0 mM of OR21 (OR1), 0.1 mM (HL60) or 0.5 mM (KG1a) of venetoclax and OR21 and venetoclax (OR+Ven) combination treatment. n.s. indicated not significant.
Funding
Shinnihon Foundation of Advanced Medical Treatment Research (公益財団法人 新日本先進医療研究財団)
Takeda Science Foundation (TSF)
Japan Medical Association (JMA)
MEXT | Japan Society for the Promotion of Science (JSPS)
Ohara Pharmaceuticals (Ohara)
History
ARTICLE ABSTRACT
The standard treatment for elderly patients with AML is Ven combined with HMAs. OR21, a new oral HMA plus Ven showed synergistic antileukemia effects in vitro and vivo, suggesting that the combination of OR2100 plus Ven is a promising candidate oral therapy for AML.